Skip to main content Accessibility help
×
Home

Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil

  • M H Araujo-Melo (a1), A M Meneses (a2), A O Schubach (a1), J S Moreira (a1), F Conceição-Silva (a3), M M Salgueiro (a1), M I F Pimentel (a1), M Araújo-Silva (a1), R V C Oliveira (a4), C N Carmo (a5) and C M Valete-Rosalino (a1)...

Abstract

Objective:

To evaluate dizziness in patients receiving meglumine antimoniate for the treatment of mucosal leishmaniasis.

Materials and methods:

We retrospectively studied 127 patients treated at the Laboratory of Leishmaniasis Surveillance, Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, between 1 January 1989 and 31 December 2004.

Results:

A low dose of meglumine antimoniate (5 mg/kg/day) was used in 86.6 per cent of patients; a dose of 10 mg/kg/day or higher was used in 13.4 per cent of patients. Dizziness was reported by 4.7 per cent of patients. The adjusted odds ratios were 7.37 for dizziness in female patients, 4.9 for dizziness in patients aged 60 years or older, and 7.77 for dizziness in the presence of elevated serum lipase.

Conclusion:

We suggest that dizziness may be a side effect of meglumine antimoniate, particularly in elderly individuals, in females and in patients with elevated serum lipase.

Copyright

Corresponding author

Address for correspondence: Dr Maria Helena de Araujo-Melo, Rua Conde de Bonfim, 383 Apto 202, Tijuca, Rio de Janeiro, Brazil, CEP 20 520-051. Fax:  + 55 2132832669 E-mail: mh.melo@terra.com.br

References

Hide All
1Goodwin, LG. Pentostam (sodium stibogluconate); a 50-year personal reminiscence [Historical Article]. Trans R Soc Trop Med Hyg 1995;89:339–41
2Di Lella, F, Vicenti, V, Zennaro, D, Afeltra, A, Baldi, A, Giordano, D et al. Mucocutaneous leishmaniasis: report of a case with massive involvement of nasal, pharyngeal and laryngeal mucosa. Int J Oral Maxillofac Surg 2006;35:870–2
3Amato, VS, Tuon, FF, Bacha, HA, Neto, VA, Nicodemo, AC. Mucosal leishmaniasis: current scenario and prospects for treatment. Acta Trop 2008;105:19
4Vianna, G. About the treatment of cutaneous leishmaniasis [in Portuguese]. An. Paul Med Cir 1914;2:167–9
5Berman, JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 1988;10:560–86
6Herwaldt, BL, Berman, JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296306
7Azeredo-Coutinho, RB, Mendonca, SC. An intermittent schedule is better than continuous regimen of antimonial therapy for cutaneous leishmaniasis in the municipality of Rio de Janeiro, Brazil. Rev Soc Bras Med Trop 2002;35:477–81
8Azeredo-Coutinho, RB, Mendonca, SC, Callahan, H, Portal, AC, Max, G. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (Glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. J Parasitol 2007;93:688–93
9Ministério da Saúde. Manual Monitoring of Cutaneous Leishmaniasis [in Portuguese]. Brazil: Fundação Nacional de Saúde, 2007
10Oliveira-Neto, MP, Schubach, A, Araujo, ML, Pirmez, C. High and low doses of antimony (Sbv) in American cutaneous leishmaniasis. A five years follow-up study of 15 patients. Mem Inst Oswaldo Cruz 1996;91:207–9
11Oliveira-Neto, MP, Schubach, A, Mattos, M, Goncalves-Costa, SC, Pirmez, C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 1997;57:651–5
12Oliveira-Neto, MP, Schubach, A, Mattos, M, Goncalves-Costa, SC, Pirmez, C. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol Biol (Paris) 1997:45:496–9
13Oliveira-Neto, MP, Mattos, M, Pirmez, C, Fernandes, O, Goncalves-Costa, SC, Souza, CF et al. Mucosal leishmaniasis (“espundia”) responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo 2000;42:321–5
14Schubach, A, Miekeley, N, Mortari, SR, Moreira, JS, Conceição-Silva, F, Salgueiro, MM et al. Studies on the metabolism of antimony and its species in the treatment of cutaneous leishmaniasis with low doses of antimonials [in Portuguese]. Int Rev Soc Bras Med Trop 2002;35:102–3
15Schubach, AO, Marzochi, KBF, Moreira, JS, Schubach, TMP, Araújo, ML, Francesconi-do-Vale, AC et al. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate. Int Rev Soc Bras Med Trop 2005;38:213–17
16Cuce, LC, Belda, W Jr, Dias, MC. Renal changes caused by pentavalent antimonial (Glucantime) hypersensitivity in American tegumentary leishmaniasis. Rev Inst Med Trop Sao Paulo 1990;32:249–51
17Gasser, RA, Magill, AJ, Oster, CN, Franke, ED, Grogl, M, Berman, JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994;18:8390
18Passos, VMA, Barreto, SM, Romanha, AJ, Krettli, AU, Volpini, AC, Gontijo, CMF et al. Cutaneous leishmaniasis in the metropolitan area of Belo Horizonte: clinical, laboratory, therapeutic and evolutionary aspects [in Portuguese]. Rev Soc Bras Med Trop 2001;34:512
19Araújo, F. Vertigo in the elderly [in Portuguese]. Folha Méd (BR) 1994;108:512
20Grimby, A, Rosenhall, U. Health-related quality of life and dizziness in old age. Gerontology 1995;41:286–98
21Ensrud, KE, Nevitt, MC, Yunis, C, Hulley, SB, Grimm, RH, Cummings, SR. Postural hypotension and postural dizziness in elderly women. The study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. Arch Intern Med 1992;152:1058–64
22Colledge, NR, Wilson, JA, Macintyre, CC, MacLennan, WJ. The prevalence and characteristics of dizziness in an elderly community. Age Ageing 1994;23:117–20
23Colledge, NR, Barr-Hamilton, RM, Lewis, SJ, Sellar, RJ, Wilson, JA. Evaluation of investigations to diagnose the cause of dizziness in elderly people: a community based controlled study. BMJ 1996;313:788–92
24Tinetti, ME, Williams, CS, Gill, TM. Dizziness among older adults: a possible geriatric syndrome. Ann Intern Med 2000;132:337–44
25Tinetti, ME, Williams, CS, Gill, TM. Health, functional, and psychological outcomes among older persons with chronic dizziness. J Am Geriatr Soc 2000;48:417–21
26Lopez-Escamez, JA, Lopez-Nevot, A, Gamiz, MJ, Moreno, PM, Bracero, F, Castillo, J et al. Diagnosis of common causes of vertigo using a structured clinical history [in Spanish]. Acta Otorrinolaringol Esp 2000;51:2530
27Kao, AC, Nanda, A, Williams, CS, Tinetti, ME. Validation of dizziness as a possible geriatric syndrome. J Am Geriatr Soc 2001;49:72–5
28Hearing loss and dizziness in the elderly: drugs and other associated factors [in Portuguese]. In: http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/ [25 June 2009]
29Katsarkas, A. Dizziness in aging: the clinical experience. Geriatrics 2008;63:1820
30Davis, LE. Dizziness in elderly men. J Am Geriatr Soc 1994;42:1184–8
31Lawson, J, Fitzgerald, J, Birchall, J, Aldren, CP, Kenny, RA. Diagnosis of geriatric patients with severe dizziness. J Am Geriatr Soc 1999;47:12–7
32Piker, EG, Jacobson, GP, McCaslin, DL. Psychological comorbidities and their relationship to self-reported handicap in samples of dizzy patients. J Am Acad Audiol 2008;19:337–47
33AIDS Table for Grading Severity of Adult Adverse Experiences. In: http://www.aactg.s-3.com [18 May 2010]
34Tuon, FF, Amato, VS. Systematic review of New World cutaneous leishmaniasis: few points to be applied to Old World leismaniasis. Int J Dermatol 2009;48:201–2
35Seligmann, H, Podoshin, L, Ben-Davis, J, Fradis, M, Goldsher, M. Drug-induced tinnitus and other hearing disorders. Drug Saf 1996;14:192212
36Hillen, ME, Wagner, ML, Sage, JI. “Subclinical” orthostatic hypotension is associated with dizziness in elderly patients with Parkinson Disease. Arch Phys Med Rehabil 1996;77:710–12
37Walker, EM Jr, Fazekas-May, MM, Bowen, WR. Nephrotoxic and ototoxic agents. Int Clin Lab Med 1990;10:323–54
38Humes, H. Insights into ototoxicity. Analogies to nephrotoxicity. Ann N Y Acad Sci 1999;28:1518
39Hyppolito, MA, Oliveira, JAA, Lessa, RM, Rossato, M. Amifostine otoprotection against cisplatin ototoxicity: guinea pig study using distortion product otoacoustic emissions and scanning electron microscopy [in Portuguese]. Rev Bras Otorrinolaringol 2005;71:268–73
40Cohen, N. The patient with dizziness. Update on vestibular disorders [in Portuguese]. Med Clin North America 1991;6:1283–93
41Dukes, MNG, Aronson, JK. Meyler's Side Effects of Drugs, 14th ed.Amsterdam: Elsevier, 2000

Keywords

Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil

  • M H Araujo-Melo (a1), A M Meneses (a2), A O Schubach (a1), J S Moreira (a1), F Conceição-Silva (a3), M M Salgueiro (a1), M I F Pimentel (a1), M Araújo-Silva (a1), R V C Oliveira (a4), C N Carmo (a5) and C M Valete-Rosalino (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed